GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”), of the important June 21, 2024 lead plaintiff deadline.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRX

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

GDRX IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

Kinross Gold

Sirius XM Holdings Inc

In 2013, the average stock price was in the range of $30-50. With inflation and rapidly rising valuations, the stock market is getting quite expensive for the everyday investor.

The 3 Most Undervalued Under-$10 Stocks to Buy in June 2024

NEW YORK, NY / ACCESSWIRE / June 3, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=82597&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on GoodRx Holdings, Inc.(GDRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) (“GoodRx” or the “Company”) on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed in the United States District Court for the Central District of California.

Class Action Announcement (GDRX): Kessler Topaz Meltzer & Check, LLP Has Filed A Securities Fraud Class Action Lawsuit Against GoodRx Holdings, Inc.

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

GDRX IMPORTANT DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 3, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=82495&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Shareholders

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

SAN DIEGO, June 02, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc. (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the “Class Period”), have until June 21, 2024 to seek appointment as lead plaintiff of the GoodRx class action lawsuit. Captioned Barsuli v. GoodRx Holdings, Inc., No. 24-cv-03282 (C.D. Cal.), the GoodRx class action lawsuit charges GoodRx as well as certain of GoodRx's top executives and directors with violations of the Securities Exchange Act of 1934.

GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

CRUCIAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced the election of Simon Patterson to its Board of Directors. Currently leading EMEA operations for the technology investment firm Silver Lake, Mr. Patterson brings to GoodRx decades of technology, strategy and management experience. Mr. Patterson also serves on the boards of IVC Evidensia, New Zealand Rugby Commercial, RAC, and ZPG, and previously served on t.

Simon Patterson Joins GoodRx Board of Directors

NEW YORK, NY / ACCESSWIRE / May 30, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=82216&wire=1 or contact Joseph E. Levi, Esq.

GoodRx Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRX

NEW YORK, NY / ACCESSWIRE / May 30, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=82219&wire=1 or contact Joseph E. Levi, Esq.

Investors who Lost Money on GoodRx Holdings, Inc.(GDRX) Should Contact Levi & Korsinsky About Pending Class Action - GDRX

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., was named to the fourth-annual TIME100 Most Influential Companies list, which highlights companies making an extraordinary impact around the world. This is the second time GoodRx has received this honor for helping Americans get the medications they need at a price they can afford. “We are thrilled to be recognized for our work to reduce the cost of prescription med.

GoodRx Named One of the 2024 TIME100 Most Influential Companies

NEW YORK , May 28, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the "Class Period"), of the important June 21, 2024 lead plaintiff deadline . SO WHAT: If you purchased GoodRx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRX

RADNOR, Pa. , May 27, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period").

GDRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GDRX Investors with Losses to Contact the Firm

GoodRx Holdings Inc (NASDAQ:GDRX) stock is on the rise today, after an upgrade from RBC to "outperform" from "market perform," with a price-target hike to $10 from $8.

GoodRx Stock Jumps After Latest Bull Note

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, the leading destination for prescription savings in the U.S., today announced it is offering discounts of up to 43% on fertility treatments based on the best available GoodRx price,1 including savings on generic and brand-name medications used during every phase of the in vitro fertilization (IVF) process. These discounts can help manage the high costs that families and individuals face when trying to expand their families. Cost is one of the major.

GoodRx Offers Discounts of Up to 43% On Fertility Treatments

NEW YORK , May 21, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the "Class Period"), of the important June 21, 2024 lead plaintiff deadline . SO WHAT: If you purchased GoodRx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRX

NEW YORK, NY / ACCESSWIRE / May 18, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=80576&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class Action - GDRX

LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=80326&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against GoodRx Holdings, Inc. (GDRX) Seeking Recovery for Investors – Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) securities during the period of September 23, 2020 through November 8, 2022, inclusive (“the Class Period”). Investors have until June 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsu.

News for GoodRx Holdings Stock (GDRX)